Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3>Hyperactivity of T lymphocytes might play an important role in the pathogenesis of primary Sjögren's syndrome (pSS). CD226/T cell immunoglobulin and ITIM domain (TIGIT) pathway is a newly identified immune checkpoint involved in the pathogenesis of cancer and rheumatic diseases. However, its role in the pathophysiology of pSS is obscure. Hence, this study aimed to explore the potential role of CD226/TIGIT expression on T cells in the pathogenesis of pSS.<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3>In patients with pSS, other rheumatic disease controls (DCs), and healthy controls (HCs), the expression of CD226 and TIGIT on T cells along with their activity following stimulation were detected by flow cytometry. The correlations between the expression of CD226 and TIGIT on T cells and clinical data were analyzed.<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3>The frequencies of CD226/TIGIT expressing CD4+ and CD8+ T cells were significantly higher in patients with pSS than in HCs and DCs. Among them, the TIGIT/CD226 expressing CD4+ T cells closely correlated with pSS disease activity: the percentages of CD4+CD226+ and CD4+TIGIT+ T cells were significantly higher in the active pSS than the inactive pSS. The proportion of CD4+TIGIT+ T cells positively correlated with the erythrocyte sedimentation rate. Further in vitro analysis revealed that CD4+CD226+ T cells exerted superior effector function than the CD226- counterparts in both pSS and HCs. TIGIT was preferably expressed on activated cells, and the activity of CD4+TIGIT+ T cells was comparable with CD4+TIGIT− T cells in HCs. However, in pSS, CD4+TIGIT+ T cells showed enhanced activity than the CD4+ TIGIT− T cells.<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3>CD226/TIGIT checkpoint molecules were over-expressed on T cells in pSS. Proportional and functional alteration of CD226/TIGIT expressing CD4+ T cells may be involved in the pathogenesis of pSS, and be a potential novel therapeutic target for the disease.

Caveolin-1 restrains pathogenic T follicular helper cell response in primary Sjögren’s syndrome

Follicular Helper T Cells and Follicular Regulatory T Cells in the Immunopathology of Primary Sjögren's Syndrome

Follicular helper T cells and follicular regulatory T cells in the immunopathology of primary Sjogren's syndrome

Tph Cells Expanded in Primary Sjögren’s Syndrome

Advances in the Pathogenesis and Treatment of Primary Sj(o)gren's Syndrome

Mycophenolate for the Treatment of Primary Sjögren's Syndrome.

Immune skew of follicular helper T cells and effector T cells in patients with Sjögren's syndrome

Unraveling the transcriptome-based network of tfh cells in primary sjogren syndrome: insights from a systems biology approach

Alteration of CD226/TIGIT immune checkpoint on T cells in the pathogenesis of primary Sjögren's syndrome

Single-Cell RNA Sequencing Reveals the Expansion of Cytotoxic CD4+ T Lymphocytes and a Landscape of Immune Cells in Primary Sjögren’s Syndrome

Autoantibodies against interferon-γ reduce the frequency of pulmonary fibrosis and concentration of C-reactive protein in patients with primary Sjögren's syndrome.

Tissue-specific activation of Myd88-dependent pathways governs disease severity in primary Sjögren's syndrome

Single-cell transcriptomic analysis uncovers heterogeneity in the labial gland microenvironment of primary Sjögren's syndrome

The Multiple Roles of B Cells in the Pathogenesis of Sjögren’s Syndrome

The Clinical Relevance of IL-17-Producing CD4+CD161+ Cell and Its Subpopulations in Primary Sjögren's Syndrome

Pharmacological Inhibition of Glutaminase 1 Normalized the Metabolic State and CD4+ T Cell Response in Sjogren’s Syndrome

The relationship between peripheral T follicular helper cells and disease severity in systemic sclerosis

Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome

Pharmacological Inhibition of Glutaminase 1 Normalized the Metabolic State and CD4+T Cell Response in Sjogren's Syndrome

Proteasome Inhibition Suppresses Th17 Cell Generation and Ameliorates Autoimmune Development in Experimental Sjögren’s Syndrome

Aryl Hydrocarbon Receptor Activation Drives Polymorphonuclear Myeloid-Derived Suppressor Cell Response and Efficiently Attenuates Experimental Sjögren's Syndrome.